- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00345826
Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia
Long-Term Safety and Efficacy of Dasatinib (BMS-354825) in Subjects Who Experienced Clinical Benefit on Protocol CA 180-002
RATIONALE: Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase I trial is studying the side effects of dasatinib in treating patients with chronic myelogenous leukemia or acute lymphoblastic leukemia.
Studie Overzicht
Gedetailleerde beschrijving
OBJECTIVES:
Primary
- Determine the long-term safety and tolerability of dasatinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia or acute lymphoblastic leukemia resistant or intolerant to imatinib mesylate.
Secondary
- Describe any hematologic or cytogenetic response in patients treated with this drug.
- Determine the duration of hematologic and cytogenetic response in patients using this drug during trial UCLA-0303035.
- Determine the progression-free survival and overall survival of patients treated with this drug.
OUTLINE: This is an open-label, roll-over study of protocol UCLA-0303035.
Patients receive oral dasatinib once or twice daily for 5, 6, or 7 days. Treatment repeats every 7 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed periodically for 5 years.
PROJECTED ACCRUAL: A total of 54 patients will be accrued for this study.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
California
-
Los Angeles, California, Verenigde Staten, 90095-1781
- Jonsson Comprehensive Cancer Center at UCLA
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
DISEASE CHARACTERISTICS:
Diagnosis of one of the following hematologic malignancies:
Chronic phase chronic myelogenous leukemia (CML)
In complete hematologic response after treatment on protocol UCLA-0303035, as indicated by the following criteria:
- WBC ≤ upper limit of normal (ULN)
- Platelet count < 450,000/mm^3
- No blasts or promyelocytes in peripheral blood
- Less than 5% myelocytes plus metamyelocytes in peripheral blood
- Peripheral blood basophils ≤ ULN
- No extramedullary involvement (including no hepatomegaly or splenomegaly)
- Response lasting ≥ 4 weeks after first documentation
Accelerated or blastic phase CML or acute lymphoblastic leukemia
In major hematologic response* after treatment on protocol UCLA-0303035, defined as 1 of the following:
In complete hematologic response*, as indicated by the following criteria:
- WBC ≤ ULN
- Absolute neutrophil count ≥ 1,000/mm^3
- Platelet count ≥ 100,000/mm^3
- No blasts or promyelocytes in peripheral blood
- Bone marrow blasts ≤ 5%
- Less than 5% myelocytes plus metamyelocytes in peripheral blood
- Peripheral blood basophils ≤ ULN
- No extramedullary involvement (including no hepatomegaly or splenomegaly)
No evidence of leukemia, as indicated by the following criteria:
- WBC ≤ ULN
- No blasts or promyelocytes in the peripheral blood
- Bone marrow blasts ≤ 5%
- Less than 5% myelocytes plus metamyelocytes in peripheral blood
- Peripheral blood basophils ≤ ULN
- No extramedullary involvement (including no hepatomegaly or splenomegaly)
- Absolute neutrophil count ≥ 500/mm^3 and < 1,000/mm^3 AND platelet count ≥ 20,000/mm^3 and < 100,000/mm^3
In minor hematologic response* after treatment on protocol UCLA-0303035, as indicated by the following criteria:
- Less than 15% in bone marrow and < 15% in peripheral blood
- Less than 30% blasts plus promyelocytes in bone marrow and < 30% blasts plus promyelocytes in peripheral blood
- Less than 20% basophils in peripheral blood
- No extramedullary disease other than spleen and liver NOTE: *Response confirmed after ≥ 4 weeks allowed provided there is no concurrent anagrelide or hydroxyurea during this time
- Philadelphia chromosome-positive (Ph+) disease
- Resistant or intolerant to prior imatinib mesylate
- Received and benefitted from ≥ 3 months of prior therapy with dasatinib on protocol UCLA-0303035
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 12 weeks after completion of study treatment
- No serious uncontrolled medical disorder
- No active infection that would preclude study participation
- No uncontrolled angina within the past 3 months
- No diagnosed or suspected congenital long QT syndrome
- No history of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, or torsades de pointes)
- QTc ≤ 450 msec on electrocardiogram
- No uncontrolled hypertension
- No dementia or altered mental status the would prohibit the understanding or rendering of informed consent
No history of the following significant bleeding disorders unrelated to CML:
- Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)
- Diagnosed acquired bleeding disorder in the past year (e.g., acquired antifactor VIII antibodies)
- Not involuntarily incarcerated for either psychiatric or physical (e.g., infectious disease) illness
- No patients who are imprisoned
- No clinical adverse event, laboratory abnormality, or intercurrent illness that may preclude study treatment, in the opinion of the investigator
- Bilirubin < 1.5 mg/dL
- ALT and AST < 2 times upper limit of normal (ULN)
- Creatinine < 1.5 times ULN
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
No concurrent use of the following drugs that may confer risk of torsades de pointes:
- Quinidine
- Procainamide
- Disopyramide
- Amiodarone
- Sotalol
- Ibutilide
- Dofetilide
- Erythromycin
- Clarithromycin
- Chlorpromazine
- Haloperidol
- Mesoridazine
- Thioridazine
- Pimozide
- Cisapride
- Bepridil
- Droperidol
- Methadone
- Arsenic
- Chloroquine
- Domperidone
- Halofantrine
- Levomethadyl
- Pentamidine
- Sparfloxacin
- Lidoflazine
- No other concurrent treatment for CML except for hydroxyurea for a 2-week duration
- No concurrent medications that inhibit platelet function (e.g., aspirin, dipyridamole, epoprostenol, eptifibatide, clopidogrel, cilostazol, abciximab, ticlopidine, or any nonsteroidal anti-inflammatory drug)* except for hydroxyurea or anagrelide
- No concurrent anticoagulants (e.g., warfarin or heparin/low molecular weight heparin [e.g., danaparoid, dalteparin, tinzaparin, or enoxaparin]) except as prophylaxis for catheter thrombosis and/or heparin flushes for IV lines* NOTE: *Allowed if received previously on UCLA-0303035
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Dasatinib
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Long term safety and tolerability
Tijdsspanne: 5 years
|
5 years
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Charles Sawyers, MD, Jonsson Comprehensive Cancer Center
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per histologisch type
- Neoplasmata
- Beenmergziekten
- Hematologische ziekten
- Myeloproliferatieve aandoeningen
- Leukemie
- Leukemie, myeloïde
- Leukemie, Myelogeen, Chronisch, BCR-ABL Positief
- Moleculaire mechanismen van farmacologische werking
- Enzymremmers
- Antineoplastische middelen
- Proteïnekinaseremmers
- Dasatinib
Andere studie-ID-nummers
- CDR0000480396
- UCLA-0509010-01
- BMS-CA180039
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op dasatinib
-
Bristol-Myers SquibbVoltooidFarmacokinetische studie bij gezonde deelnemersVerenigde Staten
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Voltooid
-
Hyoung Jin KangNog niet aan het wervenAcute lymfoblastische leukemie, pediatrisch
-
Xspray Pharma ABQPS Bioserve India Pvt LimitedVoltooid
-
National Cancer Institute (NCI)IngetrokkenHematopoietisch en lymfoïde celneoplasma | Geavanceerd lymfoom | Geavanceerd maligne solide neoplasma | Refractair lymfoom | Refractair maligne solide neoplasma | Refractair plasmacelmyeloomVerenigde Staten
-
National Cancer Institute (NCI)NRG OncologyBeëindigdRecidiverend eileidercarcinoom | Recidiverend ovariumcarcinoom | Recidiverend primair peritoneaal carcinoom | Ovarieel heldercellig cystadenocarcinoom | Endometrium Clear Cell Adenocarcinoom | Terugkerende baarmoedercorpuskankerVerenigde Staten
-
Jonsson Comprehensive Cancer CenterBristol-Myers SquibbVoltooid
-
Peking University Cancer Hospital & InstituteOnbekendGastro-intestinale stromale tumorChina
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)Voltooid
-
Kanto CML Study GroupOnbekendMyelogene leukemie, chronische, chronische faseJapan